Table 1.
Prebaseline characteristics and ASCVD outcomes of 233,696 patients with diabetes with or without SH events
| No SH event (N = 231,517) | SH event (N = 2,179) | |
|---|---|---|
| A. Characteristics | ||
| Sex (female) | 110,173 (47.6) | 1,025 (47.0) |
| Age, years, mean (SD) | 63.57 (13.5) | 67.84 (15.0) |
| Age category, years | ||
| 18–40 | 10,869 (4.7) | 115 (5.3) |
| 40–65 | 111,397 (48.1) | 692 (31.8) |
| 65–75 | 60,518 (26.1) | 582 (26.7) |
| 75–85 | 37,109 (16.0) | 558 (25.6) |
| >85 years | 11,624 (5.0) | 232 (10.6) |
| Race/ethnicity | ||
| White | 103,875 (44.9) | 1,018 (46.7) |
| African American | 22,840 (9.9) | 362 (16.6) |
| Asian | 47,946 (20.7) | 243 (11.2) |
| Latino | 39,564 (17.1) | 334 (15.3) |
| Other/unknown | 17,292 (7.5) | 222 (10.2) |
| HbA1c (%), last prebaseline, mean (SD) | 7.42 (1.50) | 7.89 (1.89) |
| LDL-C (mg/dL), last, mean (SD) | 87.28 (31.1) | 82.57 (31.8) |
| BMI, kg/m2, mean (SD) | 31.38 (7.17) | 30.02 (7.26) |
| Diabetes, type 2 | 221,267 (95.6) | 1,872 (85.9) |
| Medication use | ||
| Insulin | 55,846 (24.1) | 1,515 (69.5) |
| Sulfonylurea | 90,745 (39.2) | 952 (43.7) |
| Other OHA | 129,868 (56.1) | 825 (37.9) |
| Smoking (ever) | 95,627 (41.8) | 1,119 (51.5) |
| Hypertension | 199,758 (86.3) | 2,028 (93.1) |
| Hyperlipidemia (low HDL, high TC) | 54,681 (25.6) | 392 (20.7) |
| Prevalent ASCVD | 13,699 (5.9) | 332 (15.2) |
| SH events in previous 2 years (yes/no) | 1,831 (0.8) | 287 (13.2) |
| Charlson comorbidity score (including DM), mean (SD) | 2.43 (1.95) | 4.22 (2.38) |
| eGFR (mL/min/1.73 m2), last prebaseline, mean (SD) | 78.17 (24.0) | 60.95 (29.3) |
| Resides in most deprived neighborhood quartile | 47,932 (20.9) | 529 (24.4) |
| B. ASCVD outcomes | ||
| Nonfatal MI | 5,823 (2.5) | 119 (5.5) |
| Nonfatal stroke | 4835 (2.1) | 110 (5.0) |
| CHD (fatal) | 358 (0.2) | 10 (0.5) |
| Stroke (fatal) | 358 (0.2) | 10 (0.5) |
Data are n (%) unless otherwise indicated. In part A, all differences P < 0.0001 except sex, P = 0.61. In part B, all differences P < 0.0001 except stroke, P = 0.0004. Outcomes from baseline to end of follow-up. DM, diabetes; CHD, coronary heart disease; MI, myocardial infarction, OHA, oral hypoglycemic agent; TC, total cholesterol.